Olcadil

Quick links to important sections

Olcadil

Method of action: Psychoanaleptics, Psycholeptics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olcadil

Property Description
Active ingredient Cloxazolam
Form Tablet (Oral)
Pharmacological class Benzodiazepine Derivative, Anxiolytic
General purpose Reducing nervous tension and agitation
Origin Synthetic

Olcadil: Defining the Drug Entity and Pharmacological Class

Olcadil is a trade name for the synthetic chemical entity Cloxazolam, which is structurally categorized as an oxazolobenzodiazepine. This substance is classified within the Psycholeptic pharmacological group, carrying the Anatomical Therapeutic Chemical (ATC) code N05BA22. Cloxazolam's fundamental action is that of an anxiolytic, meaning its core purpose is to address states of heightened nervousness and worry by acting as a depressant on the central nervous system (CNS). Its use in managing tension-related states characterizes its role as a member of the benzodiazepine derivative class.

Composition and Form: Unique Features of Cloxazolam

The active ingredient in this medication is Cloxazolam (INN), typically supplied as a single-ingredient product in a solid tablet form intended for oral administration. A key distinguishing feature of this compound is its classification as a prodrug; Cloxazolam is metabolized by the liver into its active compound, chlordesmethyldiazepam (Delorazepam), which provides the sustained, long-acting therapeutic effect. This pharmacokinetic profile differentiates it from some immediate-acting anxiolytics, offering a prolonged duration of action suitable for continuous management.

General Purpose: Why is Olcadil Used?

Olcadil's primary general purpose is to promote feelings of calmness and mental composure by reducing overall nervous excitability. The anxiolytic effect is achieved by enhancing the activity of the body's natural inhibitory pathways in the brain. By facilitating a move away from states of nervous arousal, the drug is typically used in scenarios where persistent feelings of elevated tension, generalized nervousness, or agitation compromise mental tranquility.

What side effects are possible with Olcadil?

Possible side effects and safety information

Olcadil (Cloxazolam) is classified as a central nervous system (CNS) depressant, and its safety profile is primarily structured around effects on the neurological and psychiatric systems. The most commonly documented adverse reactions in regulatory sources are related to CNS depression, including drowsiness (somnolence), fatigue, ataxia (lack of coordination), and diplopia (double vision).


Safety Classifications and Organ Systems

The adverse reactions are grouped by System-Organ Class (SOC) in official labeling. Effects are noted across Nervous System Disorders, including slurred speech (dysarthria) and headache, and Psychiatric Disorders, such as anterograde amnesia and paradoxical reactions (e.g., increased agitation, anxiety, or aggression), the latter occurring in rare circumstances.


Serious Adverse Reactions and Duration Risks

Regulatory documents highlight the potential for serious adverse reactions, including respiratory depression, coma, and even death, especially when Cloxazolam is used concomitantly with other CNS depressants, notably opioids. The label specifies that the risk of developing physical dependence and tolerance (loss of efficacy) increases with the duration and dose of treatment. Abrupt discontinuation after regular use can lead to a severe withdrawal syndrome, which may include serious manifestations like convulsions.


Population-Specific Constraints

The use of Cloxazolam is associated with specific safety constraints for certain patient groups. Older adults are officially noted to have increased sensitivity to CNS effects, raising the risk of falls and fractures. The medication is contraindicated in conditions like severe hepatic failure, Myasthenia Gravis, and severe respiratory failure, as defined by official regulatory safety limits.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Olcadil (Cloxazolam) is defined by a spectrum of Central Nervous System (CNS) Depression as documented in regulatory labeling. Officially documented manifestations range from mild symptoms like somnolence, lethargy, ataxia (impaired coordination), and slurred speech, progressing to severe outcomes.


Life-Threatening Manifestations

The regulatory profile highlights the risk of profound CNS depression, coma, and respiratory depression, which may lead to respiratory arrest and hypotension. The risk of death is significantly amplified, as stated in official labeling, when Cloxazolam is co-ingested with other CNS depressants, such as alcohol or opioids.


Emergency Actions and Supportive Care

The official guidance mandates that individuals seek immediate medical attention for any suspected overdose and contact emergency services for signs of severe sedation or breathing difficulty. Management is based on supportive care, including maintaining an adequate airway and treating severe hypotension with vasopressors and IV fluids. The antidote Flumazenil is available but is documented as contraindicated in several circumstances, including chronic use or mixed ingestions, due to the documented risk of precipitating seizures.


Population Considerations

Elderly patients and individuals with severe hepatic or renal impairment are flagged in official documents as being more susceptible to Cloxazolam's accumulation and resulting toxicity.

Therapeutic Uses of Olcadil

The core therapeutic applications of Olcadil (Cloxazolam) generally center on providing symptomatic relief for conditions marked by increased discomfort or tension.

Olcadil is commonly used in the management of anxiety disorders, where patients experience persistent nervousness, worry, and pronounced mental unease. It is relevant for easing these psychological manifestations, which supports a sense of stability and contributes to improved day-to-day comfort during symptomatic periods. The medication is also applied to address associated symptoms related to physical discomfort, such as agitation, restlessness, and muscle tightness.

This medication is applied in clinical settings that involve acute or unstable symptom patterns, such as reducing nervous apprehension prior to surgery. Beyond anxiety, the medication plays a role in managing certain forms of epilepsy, particularly in conditions where additional symptomatic support is needed. This supportive role may assist with managing the intensity of severe manifestations.

Quick Fact: Relief for Nervous Tension Olcadil is used to help address symptom clusters that may become intense or disruptive, especially those stemming from heightened physiological activity and presenting with systemic or localized discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Olcadil?

Eligibility for using Olcadil (Cloxazolam) is strictly defined by regulatory documents based on patient population, physiological status, and pre-existing conditions.


Absolute Contraindications

Olcadil must not be used by the following patient groups:

  • Individuals with a known hypersensitivity to Cloxazolam, to any other benzodiazepine, or to any of the tablet's excipients.
  • Patients with severe hepatic impairment (severe liver disease) due to the risk of active metabolite accumulation.
  • Individuals experiencing severe central nervous system (CNS) depression.

Restricted and Conditional Use

Use of Olcadil is permitted but restricted for certain populations who require careful monitoring or dose reduction:

  • Elderly patients require a lower starting dosage and close monitoring due to increased sensitivity and risk of adverse effects.
  • Patients with renal or hepatic impairment (non-severe) require careful monitoring to mitigate the risk of drug accumulation.
  • Pregnancy and Lactation: The medicine is generally not recommended during pregnancy, particularly the first trimester, and should be avoided by women who are breastfeeding.

Age-Related Eligibility

The primary approved population for Olcadil is adults. Use in children and adolescents (pediatric population) is not generally established or recommended for its anxiolytic indication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacodynamic and Substance Interactions

Officially documented interactions are categorized by their effect on the body's systems or by their impact on drug levels. The most significant pharmacodynamic interaction involves additive or synergistic enhancement of central nervous system (CNS) depression when Olcadil is co-administered with other CNS depressants. This includes medicinal products such as antipsychotics, sedative hypnotics, and anesthetics. Co-administration with opioids is subject to a mandatory regulatory Boxed Warning due to the risk of profound sedation and respiratory depression. The official profile also strictly addresses the substance interaction with alcohol (ethanol), which increases systemic blood levels of the drug's active substance, thereby intensifying the CNS depressant effect.

Pharmacokinetic and Clearance Considerations

The drug's exposure profile is susceptible to pharmacokinetic interactions with substances that modulate hepatic enzymes. Medicines classified as CYP2C19 inhibitors may increase the systemic exposure of the active metabolite by reducing its clearance. Conversely, certain enzyme inducers may alter the exposure profile by influencing the metabolic conversion of the parent drug. Furthermore, in patients with severe hepatic impairment, the risk of an exposure-related interaction is elevated due to impaired metabolic capacity and subsequent challenges in clearing the substance from the body.

Mechanism of Action

How Olcadil Works: Mechanism of Action

Targeted G Protein Activation for Signal Suppression

Olcidil's action begins by targeting the mu-opioid receptor (mu-OR) as a full agonist, specifically activating the G protein component of the receptor complex. This initiates a molecular cascade that hyperpolarizes neurons, suppressing the release of excitatory neurotransmitters involved in nociceptive signaling.

Biased Modulation of CNS Pathways

The mechanism involves G protein-biased signaling, which results in reduced beta-arrestin-2 pathway activation. This mechanism operates in central nervous system (CNS) pathways where modulation of signaling dynamics is required, leading primarily to the inhibition of ascending nociceptive signaling.

Modulation of Involuntary Physiological Systems

Acting on mu-ORs throughout the body, the drug influences systems regulating involuntary functions, notably central respiratory drive and gastrointestinal peristalsis. The resultant physiological effects include a decrease in the respiratory rate and slowing of gut motility.

Dosage and Administration Information

Administration Scope

Property Instruction
Route of administration The medication is supplied for Oral intake in tablet form.
Dosing schedule (Adults) The usual total daily dose ranges from 3 mg to 12 mg. A dose up to 100 mcg/kg is described for pre-surgical use.
Age-group administration rules For older adults (elderly), a dosage decrease is recommended due to potential increased sensitivity.
Special procedural conditions The therapeutic dose must be individually determined; pre-surgical administration is typically 1 to 2 hours before the intervention.

Instruction Classifications (High-Level)

Property Classification
Administration method type Oral
Frequency pattern Divided Daily Dosing (Typically split into two or three administrations)
Use-context constraints Short-term use only; Requires gradual discontinuation; Dose titration necessary

Resulting Procedural Structure

Official step sequence:

  • The total daily dose is established within the 3 mg to 12 mg range through gradual individual adjustment.
  • The established total daily dose is administered orally, typically divided into two separate administrations.
  • Treatment duration is strictly limited to a short course, with a maximum duration of a few weeks, including the required reduction period.
  • Treatment must conclude with a gradual dose reduction until complete discontinuation.

Connection to the overall use protocol

The administration protocol for Olcadil is structured around a short-term commitment, defining a clear beginning and end point for therapy. The protocol involves precise oral administration and divided daily dosing to maintain a consistent therapeutic concentration. This framework is further governed by a necessary titration period to establish the initial dose, and a mandatory tapering process for treatment cessation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Olcadil (Cloxazolam)

The research record for Cloxazolam explores its use as a member of the benzodiazepine class. Studies examine its use in conditions involving tension and anxiety, as well as its application in specific supportive research contexts. This overview details the types of research conducted, the outcomes they measured, and areas where evidence remains limited or uncertain.


Evidence for Use in Anxiety and Nervous Tension

Research related to using Cloxazolam for symptoms of anxiety and general nervous tension typically employs short-term Randomized Controlled Trials (RCTs). These studies examined how symptoms change over time in adult outpatients diagnosed with anxiety disorders or experiencing notable psychological strain.

Researchers monitored patient outcomes related to both the mental experience of worry and physical signs of tension. In these trials, the research so far describes changes measured in anxiety scale scores for the observed populations during the short treatment windows.

Research describes findings related to fewer discontinuations attributed to lack of observed effect in short-term trials when compared to placebo. Comparative trials have documented variations in measured outcomes when Cloxazolam was assessed against other treatments, noting that findings can be heterogeneous.

The evidence mainly contributes to understanding short-term symptom patterns, as the follow-up durations were limited. Long-term effects are not fully established by the core trials, meaning that data for extended use or for the long-term stability of the observed patterns are still emerging or remain insufficient.


Evidence for Use in Specific Supportive Roles

One such area is research exploring nervous apprehension prior to a procedure. Studies report patterns related to measured changes in alertness and anxiety scores in this specific, acute context. Cloxazolam was also evaluated in an adjunctive capacity for some forms of intractable epilepsy—conditions where primary treatments were not sufficient. The research here is largely derived from smaller observational studies and open-label trials.

These studies examined outcomes related to episodic or acute changes by monitoring the frequency of seizures. Findings describe patterns related to a measured change in seizure frequency for some patients in the observed groups. The certainty remains low for this indication due to the research being based on modest sample sizes and the lack of large, placebo-controlled RCTs.

Frequently Asked Questions (FAQ)

Common questions about Olcadil (FAQ)

Q: How quickly does Olcadil start to work after taking it?

According to official product information, the active substance is rapidly absorbed after being taken orally. The body metabolizes the drug into an active compound, which reaches its peak concentration in the bloodstream approximately two to three hours after the dose.

Q: Does Olcadil cause problems with memory or concentration?

Regulatory documents indicate that central nervous system effects such as difficulty concentrating and amnesia (a form of memory loss) are potential undesirable effects. These effects are cited as the basis for the official warning that the medication may impact reaction time and mental function.

Q: Does Olcadil make you feel sleepy or tired during the day?

Official safety documents list somnolence (drowsiness) and fatigue as among the most commonly reported undesirable effects of Olcadil. These sedating effects are described as often occurring at the beginning of treatment.

Q: How long does the effect of a single Olcadil tablet usually last?

Olcadil is classified as a prodrug that is converted by the body into a substance recognized as a long-acting benzodiazepine compound. This process contributes to a prolonged therapeutic effect that extends beyond the initial hours after administration.

Q: Does Olcadil affect the liver or kidneys?

Official regulatory documents state that Olcadil is contraindicated (should not be used) in patients with severe hepatic (liver) impairment. Patients with non-severe hepatic or renal impairment are noted to require close monitoring, as the drug is processed through these organs.

Q: Is it safe to drive or operate machinery while taking Olcadil?

Official product information warns that certain activities may be affected due to the potential for side effects, including sedation, difficulty concentrating, and impaired muscle function. Official product information warns that certain activities may be affected due to the potential for side effects, including sedation, difficulty concentrating, and impaired muscle function.

Q: Does Olcadil interact with herbal supplements like St. John's Wort?

Official documents for this class of medicine caution that certain herbal products, such as St. John's Wort, can alter the body's breakdown of the drug. Such interactions may result in an altered concentration of the medicine in the bloodstream, potentially impacting its overall effect or safety profile.

Q: What are the withdrawal symptoms described in official sources if Olcadil is stopped?

Regulatory documents warn that stopping treatment abruptly after regular use can lead to a severe withdrawal syndrome, which may include serious effects like convulsions. The official documentation also notes that mild withdrawal symptoms can occur, such as trouble sleeping and a depressed mood.

Q: Why do some people feel dizzy or unsteady after taking Olcadil?

Official safety information lists dizziness and ataxia (a lack of muscle coordination or unsteadiness) as commonly reported side effects. These central nervous system effects are described in official documents as potential causes of unsteadiness.

Q: Is it true that Olcadil can cause changes in mood or behavior?

Official safety documents note potential effects on psychiatric systems, including the occurrence of paradoxical reactions in rare circumstances. These paradoxical reactions may include changes such as increased agitation or aggression.

Q: Are there any long-term effects of using Olcadil that have been researched?

The research overview states that long-term effects are not fully established by the core trials. The research overview concludes that data for use over extended periods or for the long-term stability of observed patterns remain insufficient.

Q: Is Olcadil approved for use in children or teenagers?

The primary approved population for Olcadil is adults. Official documents state that use in the pediatric population, which includes children and adolescents, is not generally established or recommended for its anxiolytic indication.

Q: Does Olcadil interact with cold or flu medications?

Official documents indicate that Olcadil may enhance the effects of other central nervous system (CNS) depressants. Some cold and flu medications contain ingredients, such as certain sedative antihistamines, that belong to this class of CNS depressants.

Q: Does Olcadil have a risk of paradoxical reactions (opposite effect)?

Official safety information notes the potential for paradoxical reactions—effects opposite to the intended use, such as increased agitation—to occur. These reactions are listed as potential undesirable effects reported in rare circumstances.

Q: What does the research say about the effectiveness of Olcadil for generalized anxiety?

Research related to Cloxazolam for symptoms of anxiety typically involves short-term, randomized controlled trials (RCTs). These studies examine how symptoms change over time in adult outpatients diagnosed with anxiety disorders or experiencing notable psychological strain.

Q: Why do official documents mention that Olcadil is for short-term use?

The regulatory label specifies short-term use because the risk of developing physical dependence and tolerance (loss of efficacy) is described in official documents as increasing with the duration of treatment. This restriction is a safety measure tied to the reported risks.

Q: Are there different strengths or forms of Olcadil available?

Olcadil is typically supplied as a tablet intended for oral use. Official product listings indicate that different strengths, such as 1 mg, 2 mg, and 4 mg tablets, may be available, depending on the market and specific product formulation.

Q: Does Olcadil have a 'black box warning' in the US, and what does it concern?

As a medicine belonging to the benzodiazepine class, Olcadil is subject to a mandatory regulatory Boxed Warning. This Boxed Warning concerns the serious risks of profound sedation, respiratory depression, coma, and death when the medicine is used at the same time as opioid medications.

Q: Is it possible to become dependent on Olcadil?

Official safety information confirms that the risk of developing physical dependence increases with the dose and the duration of treatment. Regulatory information for the class also describes physical and psychological dependence as concepts separate from the clinical diagnosis of drug addiction.

Q: Do I need to change my activities while I am using Olcadil?

The official product warning regarding the ability to drive and operate heavy machinery points to the potential that certain daily activities may be affected while using the medication. This is based on the risk of impaired coordination and reaction time.

Q: Are there any common conditions or medical issues that could make Olcadil less effective?

Official documents note that medicines or conditions that promote the action of certain enzyme inducers may accelerate the body's breakdown of the drug. This accelerated clearance may potentially lead to a reduced clinical effect.

Q: How does the body change Olcadil into its active form?

Olcadil is classified as a prodrug, meaning it is initially inactive and requires metabolism by the body. The liver is primarily responsible for converting the drug into its active compound, chlordesmethyldiazepam, which provides the therapeutic effect.

Q: Can Olcadil be stopped suddenly without issues?

Official instructions mandate a gradual dose reduction (tapering) until complete discontinuation of the medicine. Abrupt cessation is warned against, as official documents indicate it can precipitate a severe withdrawal syndrome, including the potential for convulsions.

How should Olcadil be stored and disposed of?

Storage Requirements

Olcadil (Cloxazolam) tablets must be stored at Controlled Room Temperature, typically defined as 20^circ to 25 C (68^circ to 77 F), with excursions permitted up to 30 C. The medication requires protection away from excessive heat, moisture, and light to maintain product stability and must not be frozen.

All medicines must be stored in a secure place out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Instructions

As a controlled substance, Olcadil must be disposed of properly to prevent misuse. The preferred method is using an authorized drug take-back program or mail-back option. If these are unavailable, the tablets may be disposed of in the household trash only after being mixed with an undesirable substance (like dirt or coffee grounds) and sealed in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olcadil found in:

A-Z Index: